Cancer News and Research

Latest Cancer News and Research

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.

15 Oct 2009

Veterans Affairs establishes service-connection benefits for Vietnam Veterans

Relying on an independent study by the Institute of Medicine (IOM), Secretary of Veterans Affairs Eric K. Shinseki decided to establish a service-connection for Vietnam Veterans with three specific illnesses based on the latest evidence of an association with the herbicides referred to as Agent Orange.

15 Oct 2009

DNA Precision offers services for genetic research and healthcare research

DNA Precision has begun offering services for genetic research and healthcare research. These include gene discovery, Agilent ® microarray processing and bioinformatics. DNA Precision is a division of EcoArray, Inc., a 7-year old environmental genomics firm in Gainesville, FL.

15 Oct 2009

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Cardium Therapeutics today reported positive data from its Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of patients with chronic non-healing diabetic foot ulcers based on the Company's Gene Activated Matrix (GAM) technology platform.

15 Oct 2009

Less expensive anti-rejection drug as effective as more expensive drug, says study

A newer, less expensive drug used to suppress the immune system and prevent organ rejection in kidney and pancreas transplant patients works just as well as its much more expensive counterpart, according to a new study by researchers at Wake Forest University Baptist Medical Center.

15 Oct 2009

NIH awards grant to conduct genetic drug research on cancer and heart disease

A Virginia Tech chemist has been awarded a $2.3 million grant from the National Institutes of Health (NIH) to conduct research that will aid in the development of new heart disease and cancer medicines that have fewer side effects.

15 Oct 2009

Nano Gen Teknolojileri to distribute Fluidigm's BioMark and EP1 genetic analysis systems in Turkey

Fluidigm Corporation, the inventor of integrated fluidic circuits (IFCs), has appointed Nano Gen Teknolojileri Ltd. as its exclusive distributor for the BioMark™ and EP1™ Systems for genetic analysis in Turkey. The BioMark System provides significant advantages for digital and real-time PCR, genotyping, single-cell gene expression, cancer detection and absolute quantification.

15 Oct 2009

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed.

14 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Riga Eastern Clinical University Hospital commences treatment with the Novalis Tx radiosurgery platform

Doctors in Latvia have begun treatments using the region's first Novalis Tx(TM) radiosurgery platform from Varian Medical Systems and BrainLAB. Two prostate cancer patients have been treated using Varian's RapidArc® radiotherapy technology at the Riga Eastern Clinical University Hospital.

14 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

22nd Healthcare Facilities Symposium & Expo successfully celebrated

The 22nd Healthcare Facilities Symposium & Expo (HFSE) celebrated yet another successful showing at its annual conference, held September 30 - October 2, 2009 at Chicago’s famed Navy Pier. Despite industry-wide concerns about the economy’s impact on tradeshows, HFSE closed the conference unscathed with 2,199 attendees, nearly matching last year’s record high.

14 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Progenics Pharmaceuticals, Inc. today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth under which Progenics is regaining all worldwide rights to the RELISTOR® franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to Wyeth Pharmaceuticals.

14 Oct 2009

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Women with breast cancer reduced stress and improved their mental health and emotional well being through the Transcendental Meditation technique, according to a new study published in the current issue of the peer-reviewed Integrative Cancer Therapies (Vol. 8, No. 3: September 2009).

14 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Study: Psychiatrists can distinguish competent defendants from incompetent ones

Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?

14 Oct 2009

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced that a presentation on L-DOS47 formulation and analytical method development will be made at the "Formulation Strategies for Protein Therapeutics" conference to be held on October 13 to 15, 2009, in Raleigh, North Carolina. The conference is sponsored by IBC Life Sciences.

14 Oct 2009

O-Cedar's initiative for breast cancer awareness

Fifteen women emerged from 47,000 votes on over 700 essay entries as the 2009 winners of the O-Cedar "Hope Helpers Awards" national essay contest. The essay contest awards each winner $1,000 to help them fulfill a wish or dream that will make life easier for those affected by breast cancer.

14 Oct 2009